DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Medtech (379)

Interventional Cardiology Devices | Medtech 360 | Market Analysis | US | 2017

Upcoming changes to the US health care policy and reimbursement landscape proposed by CMS, along with new product launches (including the highly anticipated BVS), greater patient selection scrutiny, and slipping ASPs, will continue to place downward pressure on the large, yet contracting, US IC market.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in the US, with market projections across a 10-year period.

Questions Answered in This Report:

  • The FDA approved the first BVS device in July 2016 and is expected to approve a number of new devices throughout the forecast period.

    How will the launch of these alternatives to metallic coronary stents affect the market?

    To what extent will new technologies impact the use of DES?

    What other DES and BVS products are currently being developed?

    Which other market segments will be impacted by novel device launches?

  • Upcoming changes to the US health care landscape, including MACRA and proposed CMS bundled payments, along with recent clinical trial results will significantly impact the US IC market.

    How will these changes the health care system and CMS bundled payments exert downward pressure on PCI procedure volumes?

    What are the implications of these changes and how can should competitors respond and shift their business?

    How can recent clinical trial results be leveraged to obtain a competitive advantage?

  • Despite continued overall market contraction, a number of segments, particularly imaging and niche products indicated for complex or difficult to treat lesions, continue to offer growth opportunities.

    How has the health care landscape affected the adoption of intravascular imaging catheters and pressure guidewires?

    What is the opportunity within the high-risk and complex lesion patient populations within the IC market?